DAVID SLACK, MBA, President, Acting CEO
David has a track record of innovation in business development, fundraising and in senior management positions at public and private biotech as well as large pharmaceutical companies. His deal-making experience encompasses well over $1 billion in corporate partnerships, spin-outs, startup and financings. He joined the Cend Therapeutics’ Board in October 2019 and was appointed President and acting CEO in June 2020. Most recently, David served as co-founding Chief Business Officer at Viracta Therapeutics, a company focused on virus-associated cancers. Prior to Viracta, David served as head of corporate development and strategy for Novimmune, a next generation antibody company. Previously, David served as Vice President for Business Development at leading antisense drug company, Ionis (then Isis) Pharmaceuticals, where he was responsible for several major partnerships and establishment of “satellite companies.” From the “buy side” corporate partnering perspective, David served in senior licensing positions as Rhône-Poulenc Rorer, RPR Gencell and Aventis Pharmaceuticals, where he was responsible for multiple major strategic partnerships.